ESR1 and breast cancer: Bronte et al. [31] reviewed a total of 159 ER–positive breast cancer patients between 2000 and 2008 with a median follow–up of 63 months, of whom 89 had data on AR, ER, and survival, and 24 patients with metastasis had pathological findings for primary and metastatic foci.